A randomized, double-blind, placebo-controlled, 3-period crossover study was conducted in 54 healthy adults to assess the effect of ceftaroline fosamil on the corrected QT (QTc) interval. The QT interval, corrected for heart rate using an individual correction formula (QTcIb), was determined predose and at 1, 1.25, 1.5, 2, 4, 8, 12, and 24.5 h after intravenous dosing with a supratherapeutic dose (1,500 mg) of ceftaroline fosamil, 400 mg moxifloxacin (positive control), and placebo. The pharmacokinetic profile of ceftaroline was also evaluated. At each time point following ceftaroline fosamil administration, the upper limit of the 90% confidence interval (CI) for the placebo-corrected change from predose baseline in QTcIb (⌬⌬QTcIb) was below 10 ms (maximum, 3.4 ms at 1.5 h after dosing), indicating an absence of clinically meaningful QTc increase. The lower limit of the 90% CI of ⌬⌬QTcIb for moxifloxacin versus placebo was greater than 5 ms at 5 time points (maximum, 12.8 ms at 1 h after dosing), demonstrating assay sensitivity. There was no apparent correlation between ceftaroline plasma concentrations and ⌬⌬QTcIb. The supratherapeutic dose of ceftaroline fosamil (1,500 mg) resulted in substantially greater systemic exposure to ceftaroline than previously observed with standard therapeutic doses. Ceftaroline fosamil was well tolerated after a single 1,500-mg intravenous dose, and no clinically meaningful abnormalities in laboratory values or vital signs were observed.
C eftaroline fosamil, a new, parenteral cephalosporin, is approved in the United States for the treatment of adults with acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP) caused by designated susceptible bacteria. Ceftaroline fosamil, a prodrug, is rapidly converted via plasma phosphatase enzymes to its bioactive metabolite, ceftaroline (1) . Ceftaroline exhibits broad-spectrum bactericidal in vitro activity against Grampositive organisms, including those with contemporary resistant Gram-positive phenotypes, such as methicillin-resistant Staphylococcus aureus (MRSA) and penicillin-resistant Streptococcus pneumoniae, as well as common Gram-negative pathogens (2, 3) . Like other ␤-lactam antimicrobials, the activity of ceftaroline is due to inhibition of penicillin-binding proteins, which are involved in the biosynthesis of the bacterial cell wall. Ceftaroline fosamil is available as an intravenous (i.v.) formulation. The recommended dose of ceftaroline fosamil is 600 mg every 12 h (q12h) by i.v. infusion administered over 1 h in patients 18 years of age or older with creatinine clearance (CL CR ) above 50 ml/min (4) .
The pharmacokinetics of ceftaroline have been studied over a broad range of doses in healthy subjects and in special populations. Systemic exposure to ceftaroline increases approximately in proportion to dose within the dose range of 50 to 1,000 mg (5) . The plasma elimination half-life (t 1/2 ) of ceftaroline is approximately 2.6 h in adults with normal renal function after multiple q12h doses (4) . The primary route of elimination of ceftaroline and its metabolites is via renal excretion (5, 6) . Compared to subjects with normal renal function, the area under the plasma concentration-time curve (AUC) of ceftaroline increased by 19, 52 , and 115% in subjects with mild (CL CR of Ͼ50 to Յ80 ml/min), moderate (CL CR of Ͼ30 to Յ50 ml/min), and severe (CL CR of Ն15 to Յ30 ml/min) renal impairment, respectively. Dose adjustment is recommended for patients with moderate and severe renal impairment. Ceftaroline is not a substrate for hepatic CYP450 enzymes and does not inhibit or induce the major CYP isoenzymes in vitro. In addition, ceftaroline exhibits low (ϳ20%) binding to plasma proteins (4) . The potential for drug-drug interactions with ceftaroline therefore is considered to be low.
Numerous drugs have been associated with QT prolongation, which may be exacerbated by comorbid conditions (e.g., congenital long QT syndrome and bradycardia) and metabolic abnormalities (e.g., hypokalemia) (7) (8) (9) . Drugs associated with QT prolongation include certain antiarrhythmics, antihistamines, psychotropics, and antibiotics, notably macrolides and quinolones (7, 8) . The cephalosporin class of antimicrobials is not associated with QT prolongation. Although no effect on the QT interval was expected with ceftaroline fosamil, a formal evaluation of its potential to prolong the QT interval had not been conducted. Beginning early in clinical development, new drugs are expected to undergo a clinical electrocardiographic evaluation, typically with a single trial designed to evaluate their effect on cardiac repolarization (i.e., the so-called thorough QT/QTc study) (10) . Therefore, this study was performed to assess the effects of a single supratherapeutic i.v. dose of ceftaroline fosamil (1,500 mg) versus placebo on the QT interval corrected for heart rate (QTc) using an individual correction formula based on the baseline QT-RR slope (QTcIb) in healthy adults. The supratherapeutic dose used in this study was chosen to cover higher exposures of ceftaroline that could be seen in special populations (e.g., patients with renal impairment). Secondary objectives were to determine the difference, if any, in the effect on the QTcIb interval between male and female subjects, to evaluate differences in the effects of i.v. ceftaroline at a supratherapeutic dose and a placebo on the proportion of subjects with QTc interval data exceeding specified values and on changes in electrocardiogram (ECG) diagnostics, and to evaluate the pharmacokinetic profile, safety, and tolerability of ceftaroline fosamil at a supratherapeutic i.v. dose in healthy adults.
(A preliminary report of these results was presented at the 21st European Congress of Clinical Microbiology and Infectious Diseases, Milan, Italy, 7 to 10 May 2011.)
MATERIALS AND METHODS
Study design and subjects. The present study was a randomized, doubleblind, placebo-controlled, 3-period crossover study of a single supratherapeutic dose of i.v. ceftaroline fosamil, a single dose of i.v. placebo (negative control), and a single dose of moxifloxacin (positive control). Subjects were healthy men or women aged 18 to 45 years, with a body mass index (BMI) of 18 to 30 kg/m 2 and CL CR of Ն80 ml/min. Subjects were screened (medical history, physical examination, standard 12-lead ECG, hematology, blood chemistry, and urinalysis) up to 21 days and not less than 48 h before study drug administration. Subjects were stratified by sex, with an equal number of men and women enrolled and randomly assigned to 1 of 6 study drug sequences. Enrollment and randomization continued until a total of 54 subjects (27 male and 27 female) had been randomized. The study was conducted in accordance with ethical principles stated in the Declaration of Helsinki, and all local regulatory requirements were followed. Subjects provided informed consent, and the study protocol and amendments were approved by the Institutional Review Board at the study center.
According to the predetermined sequence, subjects received i.v. ceftaroline fosamil (1,500 mg), 0.9% saline, or moxifloxacin (400 mg), each in a final volume of 250 ml, which was infused over 1 h. A single dose of each subsequent study drug was administered 5 days after the previous dose at approximately the same time of day. The subject, investigator, and site personnel involved in the study, with the exception of pharmacy personnel, were blinded to treatment.
Electrocardiography. Continuous 12-lead digital ECG recording using a Holter ECG monitor (model H12ϩ, v3.14; Mortara Instrument, Inc., Milwaukee, WI) began 24.5 h before the first study drug administration (day 1) and up to 1 h before subsequent study drug administration (days 6 and 11) and was continued until 24.5 h after all infusions. Three ECG replicates separated by at least 1 min were extracted within the 15-min period before study drug administration (the mean of these replicates was defined as the predose baseline) and at 1, 1.25, 1.5, 2, 4, 8, 12, and 24.5 h after the start of administration. The ECGs were read at a central ECG laboratory by personnel blinded to all study information.
The primary ECG parameter was the change from predose baseline (the mean of 3 values from the ECG recordings collected within 15 min before study drug infusion) in QTcIb based on the baseline QT-RR slope for each postdose time point. The potential for QTc prolongation with ceftaroline fosamil was based on comparison to placebo. The individual correction method was selected for the derivation of the primary study endpoint, because it is recommended in regulatory guidance (10) and relevant literature (11) for thorough QT/QTc studies in compounds that do not affect the heart rate, such as ceftaroline. In order to implement this method, sufficient QT-RR measurements were collected during the predose baseline period to allow for reliable estimation of subject-specific corrections. For comparison, QTc was also calculated using Bazett's formula (QTcB) and Fridericia's formula (QTcF). The secondary ECG parameters were (i) the proportion of subjects with a postbaseline QTcIb interval of Ͼ450, 480, and 500 ms; (ii) the proportion of subjects with an increase from predose baseline in a QTcIb interval of Ͼ30 and Ͼ60 ms; and (iii) the proportion of subjects with an ECG diagnostic abnormality (QRS-complex, ST-segment, T-wave, or U-wave morphologies).
Statistical analysis of QT/QTc. The sample size calculation was based on a paired t test. This study was planned to enroll 54 subjects, with at least 48 subjects expected to be included in the ECG evaluable population. With 3 QT measurements from 48 subjects, the study would have at least 96% probability at each time point to conclude that the upper bound of the 2-sided 90% confidence intervals (CIs) for the time-matched difference (where time matched indicates the difference between treatment pairs at the same postdose time point) between the supratherapeutic ceftaroline fosamil dose and placebo in the mean change from predose baseline in QTcIb would be less than 10 ms.
The estimated treatment differences between ceftaroline and placebo in the mean change from baseline in QTcIb (⌬⌬QTcIb) at each time point and the 2-sided 90% CIs were derived using a linear mixed-effect repeatedmeasures model with the ⌬⌬QTcIb as a response, with treatment, treatment sequence, and period as fixed effects, and with subject as a random effect. In accordance with the U.S. Food and Drug Administration guidance document (10) , it would be concluded that treatment with ceftaroline fosamil did not produce a clinically meaningful prolongation of the QTc interval if the upper limit of the 90% CI for ⌬⌬QTcIb at each postdose time point was less than 10 ms. Assay sensitivity would be concluded if the lower limit of the 90% CI for the difference between moxifloxacin and placebo in ⌬⌬QTcIb exceeded 5 ms for at least 1 postdose time point near the expected maximum concentration of moxifloxacin in plasma. At each postbaseline time point, a linear mixed-effect repeated-measures model with an unstructured variance covariance for within-subject changes was used to estimate the relationship between ceftaroline plasma concentration and ⌬⌬QTcIb.
Pharmacokinetics. Blood samples to evaluate the pharmacokinetics of ceftaroline fosamil, ceftaroline, and its inactive metabolite, ceftaroline M-1, were collected in chilled heparin tubes immediately preceding study drug administration, at 30 min after the start of each study drug administration, at completion of study drug infusion, and at 65 and 75 min and 1.5, 2, 3, 4, 6, 8, 12, 18, and 24 h after the start of each study drug administration. Plasma was separated immediately and kept frozen at Ϫ70°C until it was analyzed at the Bioanalytical & Drug Metabolism Department, Forest Research Institute, Inc. (Farmingdale, NY). Samples from subjects who received placebo or moxifloxacin were not analyzed. Plasma concentrations of ceftaroline fosamil, ceftaroline, and ceftaroline M-1 were measured using a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay with a lower limit of quantitation of 50 ng/ml for each analyte.
After mixing the plasma sample with internal standard spiking solution and adding methanol to precipitate plasma protein, the analytes (ceftaroline fosamil, ceftaroline, and ceftaroline M-1) and their internal standards ([2H3] Plasma concentration-time profiles were constructed for each subject. For each plasma concentration-time curve, the following pharmacokinetic parameters were determined directly from inspection of the data or were calculated using noncompartmental methods with validated software (WINNONLIN version 5.2.1; Pharsight Corporation, Mountain View, CA): maximum drug concentration in plasma (C max ), time of maximum plasma concentration (T max ), area under the plasma concentration-time curve up to the time corresponding to the last measurable concentration (AUC 0 Ϫ t ), area under the plasma concentration-time curve from time zero to infinity (AUC 0 Ϫ ϱ ), plasma clearance (CL), t 1/2 , steady-state volume of distribution (V ss ), and volume of distribution based on the terminal phase (V z ).
Safety analysis. Throughout the duration of the study, safety assessments included adverse events (AEs), vital signs, clinical laboratory test values, and physical examinations. The occurrences of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), discontinuations because of AEs, or deaths were recorded, as was information on the intensity of AEs and relationship to study drug. Descriptive statistics of clinical laboratory results and change from baseline, as well as potentially clinically significant laboratory values, were presented.
RESULTS

Demographics.
A total of 54 healthy subjects (27 men and 27 women) were enrolled and assigned by block randomization (stratified by sex) to 1 of 6 treatment sequences in the 3-period crossover design. The median age of study participants was 24 years (range, 18 to 45 years), and the median BMI was 24.6 kg/m 2 (range, 18 to 29 kg/m 2 ). Most subjects were white (72%) and non-Hispanic (70%). Fifty-four subjects completed dosing with ceftaroline fosamil and placebo; 53 subjects completed dosing with moxifloxacin. One subject prematurely discontinued because of a TEAE following administration of placebo and was not dosed with moxifloxacin.
Electrocardiography. The largest ⌬⌬QTcIb for ceftaroline versus placebo was 0.66 ms (90% CI, Ϫ2.1 to 3.4 ms), occurring 1.5 h postdose (Table 1) (Fig. 1 ). The upper 90% CI limit for ceftaroline versus placebo was below 10 ms at every time point postdose, demonstrating that a supratherapeutic dose of ceftaroline fosamil did not cause a clinically meaningful increase in QTcIb interval. The effects of ceftaroline versus placebo on ⌬⌬QTcB and ⌬⌬QTcF were similar to those observed for ⌬⌬QTcIb, with the upper 90% CI limit at every time point postdose below 10 ms (Tables 2 and 3 ). The largest between-treatment difference in ⌬⌬QTcIb from baseline for moxifloxacin versus placebo was 15.7 ms (90% CI, 12.8 to 18.5 ms), occurring 1 h postdose (Table 4) (Fig. 1 ). The lower 90% CI limit for ⌬⌬QTcIb was greater than 5 ms at 5 time points, demonstrating assay sensitivity. The effects of moxifloxacin versus placebo on ⌬⌬QTcB and a Least-squares mean estimates and CI based on QTcIb as an independent variable in a repeated-measures linear mixed-effects model with treatment regimen, sequence, and period as fixed effects and subject as a random effect. ⌬⌬QTcIb, between-treatment difference in change from predose baseline in QTcIb; QTcIb, QT interval corrected for heart rate using an individual correction formula based on the baseline QT-RR slope; SD, standard deviations.
FIG 1
Least-squares mean difference and 2-sided 90% CI for ⌬⌬QTcIb for ceftaroline versus placebo and for moxifloxacin versus placebo. CI, confidence interval; ⌬⌬QTcIb, between-treatment difference in change from predose baseline in QT interval corrected for heart rate using an individual correction formula based on the baseline QT-RR slope. a Additional electrocardiogram parameter. ⌬⌬QTcB, between-treatment difference in change from predose baseline in QT interval using Bazett's formula; QTcB, QT interval corrected for heart rate using Bazett's formula. b Least-squares mean estimates and CI based on QTcB as an independent variable in a repeated-measures linear mixed-effect model with treatment regimen, sequence, and period as fixed effects and subject as a random effect.
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April 2013 Volume 57 Number 4 aac.asm.org 1779 ⌬⌬QTcF were similar to those observed for ⌬⌬QTcIb (Tables 5  and 6 ). The effects of ceftaroline on ⌬⌬QTcIb were similar in male and female subjects. The differences in ⌬⌬QTcIb for ceftaroline ranged from Ϫ4.4 ms (at 24.5 h) to 8.9 ms (at 1 h) for female subjects and from Ϫ13.4 ms (at 24.5 h) to 7.6 ms (at 1 h) for male subjects, and for placebo the differences ranged from Ϫ4.6 ms (at 24.5 h) to 10.6 ms (at 1 h) for female subjects and from Ϫ12.3 ms (at 24.5 h) to 10.0 ms (at 1 h) for male subjects.
Ceftaroline plasma concentrations were not correlated with time-matched, between-treatment differences in ⌬⌬QTcIb from baseline for ceftaroline versus placebo (Fig. 2) . The slope of the estimated regression line was 0.0044, indicating that there was no concentration effect for ceftaroline on the changes in QTcIb interval.
One subject had a QTcIb interval of Ͼ450 ms after receiving ceftaroline fosamil, which occurred 1.5 and 12 h after the start of ceftaroline fosamil infusion. This subject also experienced a QTcIb interval of Ͼ450 ms after receiving placebo and moxifloxacin. Ten subjects had QTcIb intervals of Ͼ450 ms after receiving moxifloxacin, and 2 subjects had QTcIb intervals of Ͼ450 ms after receiving placebo. No subjects in any treatment group had a postbaseline QTcIb interval of Ͼ480 ms. At the end of study drug infusion (i.e., C max ), 1 subject had a QTcIb interval increase of Ͼ30 ms after receiving ceftaroline, 1 subject had an increase of Ͼ30 ms after placebo, and 18 subjects had increases of Ͼ30 ms after moxifloxacin. No subjects in any treatment group had an increase from baseline in QTcIb of Ͼ60 ms. The proportions of subjects with QRS-complex, ST-segment, T-wave, or U-wave morphologies were similar between ceftaroline and placebo. Pharmacokinetics. The mean pharmacokinetic parameters for ceftaroline following a supratherapeutic dose of ceftaroline fosamil (1,500 mg i.v.) are shown in Table 7 . The mean C max and AUC 0-ϱ values of ceftaroline were 81.39 Ϯ 12.46 g/ml and 204.64 Ϯ 28.23 g · h/ml, respectively, following a single 1,500-mg dose of ceftaroline fosamil. The t 1/2 for ceftaroline was 2.59 Ϯ 0.31 h, which is consistent with previous studies with ceftaroline in subjects with normal renal function, and the T max occurred around the time of the end of study drug infusion. Ceftaroline fosamil was rapidly converted to ceftaroline and was generally only measurable in plasma for 0.5 to 1 h after the end of study drug infusion. The mean AUC 0-ϱ for ceftaroline M-1 was approximately 18% of the AUC 0-ϱ for ceftaroline (not shown). Safety. No deaths, SAEs, or severe TEAEs occurred during the study. One female subject was discontinued from the study after developing mild neutropenia on day 7 following the administration of placebo on day 6. The subject received ceftaroline fosamil on day 1 and was discontinued prior to receiving moxifloxacin. The patient's baseline absolute neutrophil count (ANC) was 2,573. The ANC decreased to 1,360 on day 7 and increased to 2,213 by day 15. The investigator assessed the event to be mild and possibly related to the study drug. No other subjects discontinued from the study because of a TEAE.
A similar percentage of subjects had TEAEs following administration of ceftaroline fosamil (37%) or moxifloxacin (36%); 20% of subjects had TEAEs following administration of placebo. Most TEAEs (90%) were assessed as mild in severity. Treatment-emergent adverse events assessed by the investigator as possibly or probably related to the study drug occurred in approximately 32% of subjects following administration of ceftaroline fosamil, 23% of subjects following administration of moxifloxacin, and 11% of subjects following administration of placebo. The most common TEAEs assessed as possibly or probably related to ceftaroline fosamil were nausea (18.5%) and vomiting (5.6%), to moxifloxacin were infusion site reactions (9.4%), headache (7.5%), and nausea (3.8%), and to placebo were nausea and diarrhea (3.7% each). No clinically meaningful abnormalities in laboratory values or vital signs were observed at any time point following any dose of study drug.
DISCUSSION
This placebo-controlled, crossover, thorough QTc study in healthy volunteers evaluated the effect of i.v. ceftaroline fosamil administered at a supratherapeutic dose of 1,500 mg on the QT interval individually corrected for heart rate. The study was conducted in accordance with the International Conference on Harmonization (ICH) guidelines on a thorough QT/QTc study (10) and used moxifloxacin as a positive control. Moxifloxacin is expected to produce an increase in QTc of approximately 10 ms following a single 400-mg dose (12) (13) (14) . Assay sensitivity, as defined in the ICH guidelines, is evaluated by looking at the lower limit of the 90% CI of ⌬⌬QTcIb for moxifloxacin versus placebo. In the present study, the lower 90% CI limit for ⌬⌬QTcIb for moxifloxacin was greater than 5 ms at 5 time points, demonstrating assay sensitivity. A single supratherapeutic dose of i.v. ceftaroline fosamil did not cause a clinically meaningful increase in ⌬⌬QTcIb compared to placebo at peak plasma concentration or at any other time. The largest between-treatment least-squares difference in time-matched ⌬⌬QTcIb interval for ceftaroline fosamil versus placebo was 0.66 ms, with 90% CI limits of Ϫ2.1 to 3.4 ms. The upper 90% CI limit was below 10 ms, indicating that the supratherapeutic dose of ceftaroline fosamil did not cause a clinically meaningful increase in QTc interval. There also were no clinically meaningful QTc increases when QTcF and QTcB were evaluated. In addition, no concentration effect for ceftaroline on changes a AUC 0-t is the area under the plasma concentration-time curve up to the time corresponding to the last measurable concentration; AUC 0-ϱ is the area under the plasma concentration-time curve from time zero to infinity; CL, plasma clearance; C max , maximum (peak) drug concentration in plasma; T max , time of maximum plasma concentration; t 1/2 , elimination half-life; V ss , volume of distribution at steady-state; V z , volume of distribution based on the terminal phase. b n ϭ 53. One subject was excluded due to an aberrant pharmacokinetic profile that was thought to be the result of partial extravascular administration of the ceftaroline fosamil dose. c T max results are expressed as medians (minimum-maximum).
in QTcIb from baseline between ceftaroline and placebo was observed. Effects of a supratherapeutic dose of ceftaroline fosamil on ⌬⌬QTcIb intervals were similar between male and female subjects. These results demonstrate the lack of effect of ceftaroline fosamil on the QTc interval and support similar findings that have been noted in patients treated with ceftaroline fosamil. Combined data from 2 large-scale phase III clinical trials (ClinicalTrials.gov identifiers NCT00424190 and NCT00423657) that compared the efficacy of ceftaroline fosamil to that of vancomycin plus aztreonam in the treatment of 1,378 adult patients with complicated skin and skin structure infections detected no prolongation in QTcF or QTcB intervals in ceftaroline fosamil-treated patients (15, 16) . Data from 2 additional large-scale phase III trials (ClinicalTrials-.gov identifiers NCT00621504 and NCT00509106) that compared ceftaroline fosamil to ceftriaxone in the treatment of 1,228 hospitalized adults with community-acquired pneumonia revealed that similar and small numbers of patients treated with ceftaroline fosamil and ceftriaxone experienced a prolongation of the QTcF interval (4 and 3 patients, respectively) or QTcB interval (6 and 5 patients, respectively) (QTcF or QTcB of Ͼ500 ms and a change from baseline of Ն60 ms) (16, 17) . Because ceftriaxone is not known to prolong the QT interval and the numbers of patients treated with ceftaroline fosamil or ceftriaxone who were observed to have QTc elevations in the community-acquired pneumonia studies were small and similar, these data support a lack of effect of ceftaroline fosamil on QTc prolongation.
The supratherapeutic dose of 1,500 mg ceftaroline fosamil resulted in substantially greater systemic exposure to ceftaroline (C max of 81.39 g/ml and AUC 0-ϱ of 204.64 g · h/ml) than that observed with the standard therapeutic dose (600 mg). The C max and AUC were approximately 3.9 and 3.7 times greater, respectively, than values reported for subjects with normal renal function on the last day of dosing with ceftaroline fosamil (600 mg q12h) for 14 days (6). There is relatively low potential for clinically meaningful increases in ceftaroline plasma concentrations due to drug-drug interactions in vivo. A more likely scenario for increased systemic exposure to ceftaroline in the clinic is failure to adjust the dose for impaired renal function. The C max and AUC values for ceftaroline observed in this study were approximately 4.6 and 1.8 times greater, respectively, than values reported for subjects with severe renal impairment who received a 400-mg dose of ceftaroline fosamil i.v. (18) . The supratherapeutic dose of ceftaroline fosamil used in the present study thus provided greater systemic concentrations of ceftaroline for QTc evaluation than those likely to be observed during routine clinical use of ceftaroline fosamil.
This study demonstrated the lack of effect of ceftaroline fosamil on the QTc interval and was designed in accordance with current regulatory guidelines for evaluating the potential of new drugs to prolong the QTc interval; however, several limitations of this type of study should be noted. The study was conducted in healthy subjects 18 to 45 years of age, which is not the intended patient population. Patients may vary substantially in terms of disease intensity, comorbidities, and concomitant medications. Balancing these factors between treatment and control groups may not be possible, making interpretation of the ECG results difficult (19) . As a result, a relatively homogeneous group of healthy subjects, as used in the current study, is generally preferred in thorough QTc studies to reduce intrinsic variability in measurement of the QTc interval. In addition, the supratherapeutic dose administered in this study resulted in systemic exposure to ceftaroline that was greater than the exposure likely to occur in patients in routine clinical use. Another limitation is that the present study only looked at effects on the QTc interval after a single dose of ceftaroline fosamil. However, accumulation of ceftaroline does not occur after multiple doses due to its short half-life (2.6 h) relative to the dosing interval (q12h), and PK parameters are similar after single and multiple doses (4) . Finally, the present study utilized a supratherapeutic dose (1,500 mg) of ceftaroline fosamil instead of the clinical dose (600 mg). Given that there was no correlation between ceftaroline plasma concentrations and ⌬⌬QTcIb (Fig. 2 ) and no effect on the QTc interval at the supratherapeutic dose, no effect of ceftaroline fosamil on the QTc interval is expected at the clinical dose.
In conclusion, at a supratherapeutic dose of 1,500 mg, ceftaroline fosamil had no clinically relevant effect on the QT/QTc interval in healthy male and female adult volunteers. No SAEs or deaths occurred during the study, and the supratherapeutic dose of ceftaroline fosamil was well tolerated in this group of 54 healthy adults.
